



游离轻链测定 选择拜定赛 Freelite® 检测


- **Freelite®** 检测是IMWG*¹⁻³指南和许多国家当地指南中唯一实名推荐的检测项目。¹⁻³
- 指南和临床评估中推荐的 cut-off 值基于Freelite®检测。
- **Freelite®** 检测被欧盟 CE 和美国 FDA 许可用于多发性骨髓瘤和AL淀粉样变性的诊断和监测

*IMWG-国际骨髓瘤工作组



IMWG 骨髓瘤定义事件阈值¹

✓ i/u FLC*比值 ≥ 100 ✓ iFLC**浓度 ≥ 100 mg/L ✓ 骨髓浸润浆细胞 > 10%



Freelite® 检测于2001年上市，用于游离轻链的检测，其临床价值：



被3000
多篇文献报导，



在不同的平台上用不同
批次的试剂得到验证



在不同地区的大队列
患者研究中得到证实



全球1000多家实验室包括
顶尖骨髓瘤中心的选择

*i/u FLC - 受累/非受累游离轻链

** iFLC - 受累游离轻链



选择拜定赛 Freelite[®] 检测， 患者安心、医者放心

- IMWG 指南实名推荐使用 Freelite[®] ^{1-3,8}
- 许多研究已经证明，游离轻链分析方法不能互换，因此改变分析方法将需要患者重建基线值 ²⁰⁻²²
- 多发性骨髓瘤的连续监测非常重要
- 使用经临床充分验证的检测来做决策，让患者的风险最小化



游离轻链检测相关的指南和临床应用建议

1. Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol* 2014; 15:e538–e548 **Freelite® mentioned by name**
2. Dispenzieri A, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia* 2009; 23:215–224 **Freelite® mentioned by name**
3. Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol* 2016; 17:e328–46 **Freelite® mentioned by name**
4. Kyle RA, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia* 2010; 24:1121–1127
5. Dimopoulos M, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. *Blood* 2011; 117:4701–4705
6. Munshi NC, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. *Blood* 2011; 117:4696–4700
7. Moreau P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. *Ann Oncol* 2017; 28:iv52–iv61
8. Bird J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). *Br J Haematol* 2009; 147:22–42 **Freelite® mentioned by name**
9. Bird J, et al. Guidelines for the diagnosis and management of multiple myeloma 2014. BCSH guideline 2014
10. Kumar SK, et al. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Multiple Myeloma V.2.2019 (Accessed 06/03/19). Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
11. Myeloma: diagnosis and management. NICE Guidelines 2016; Available from: <https://www.nice.org.uk/guidance/ng35>
12. Caers J, et al. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. *Haematologica* 2018; 103:1772–1784
13. Gillmore JD, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. *Br J Haematol* 2015; 168:207–218
14. Wechalekar AD, et al. Guidelines on the management of AL amyloidosis. *Br J Haematol* 2015; 168:186–206
15. Kumar SK, et al. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Systemic Light Chain Amyloidosis V.1.2019 (Accessed 12/12/2018). Available from: https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf
16. Comenzo RL, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light chain (AL) amyloidosis. *Leukemia* 2012; 26:2317–232
17. 中国多发性骨髓瘤诊治指南
中华内科杂志2020年5月第59卷第5期
18. 系统性轻链型淀粉样变性诊断和治疗指南（2021年修订）
中华医学杂志2021年6月15日第101卷第22期
19. Mateos M-V, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). *Blood Cancer Journal* 2020;10/102
20. Schieferdecker, A. et al. *Blood Cancer J.* 2020 Jan 9;10(1):2. doi: 10.1038/s41408-019-0267-8
21. Bossuyt, X. et al. Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. *Leukemia* 32, 1815–1818 (2018)
22. Yang, Y. et al. Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease. *Health Sci. Rep.* 2, e133 (2019).

